l 158809 has been researched along with Cognition Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, WR; Diz, DI; Hsu, FC; Olson, J; Payne, V; Robbins, ME; Tommasi, E; Wheeler, KT; Zhao, W | 1 |
| Conner, KR; Forbes, ME; Payne, VS; Riddle, DR; Robbins, ME | 1 |
2 other study(ies) available for l 158809 and Cognition Disorders
| Article | Year |
|---|---|
The AT1 receptor antagonist, L-158,809, prevents or ameliorates fractionated whole-brain irradiation-induced cognitive impairment.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cognition Disorders; Cranial Irradiation; Dose Fractionation, Radiation; Drug Evaluation, Preclinical; Imidazoles; Male; Radiation Injuries, Experimental; Rats; Rats, Inbred F344; Tetrazoles | 2009 |
Effects of the AT1 receptor antagonist L-158,809 on microglia and neurogenesis after fractionated whole-brain irradiation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Behavior, Animal; Brain; Cell Proliferation; Cognition Disorders; Dentate Gyrus; Humans; Imidazoles; Inflammation; Male; Microglia; Neurogenesis; Neurons; Radiation Dosage; Radiation Injuries, Experimental; Rats; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Time Factors | 2010 |